News: 2024.03.20
Jiangsu Quanxin Biotechnology is a clinical-stage biotechnology company focusing on biological therapies for autoimmune and allergic diseases. Today, the company was officially listed on the main board of The Stock Exchange of Hong Kong Limited and began trading, with each trading unit being 200 shares.
The listing of Quanxin Biotech is an important milestone for the Hong Kong Stock Exchange. The company's biotherapeutic products have huge potential in the field of immune and allergic diseases and will bring more opportunities to investors.
The listing of Quanxin Biotech will bring more financial support and market recognition to the company's future development. The company will continue to develop innovative biotherapeutic products to provide patients with more effective treatment options.
Quanxin Biotech adheres to the values of professionalism, innovation, cooperation and responsibility, and is committed to becoming an industry leader, promoting the development of biotechnology and improving people's quality of life.
For investors, the listing of Quanxin Biotech means more investment opportunities and potential returns. The company's biotherapeutic products are expected to be successful in the market and generate huge profits for investors.